@article{57cda69555234a5cb8f09a2ac58f650d,
title = "Evaluation of selected lichens from Iceland for cancer chemopreventive and cytotoxic activity",
keywords = "Aromatase, Cancer chemoprevention, Cytotoxicity, HL-60 cell differentiation, Icelandic plants, Lichens, Ornithine decarboxylase, Quinone reductase, Sulfatase",
author = "K. Ingolfsdottir and {Sang Kook Lee}, {Kook Lee} and Bhat, {K. P.L.} and K. Lee and Chai, {H. B.} and H. Kristinsson and Song, {L. L.} and J. Gills and Gudmundsdottir, {J. Th} and E. Mata-Greenwood and Jang, {M. S.} and Pezzuto, {J. M.}",
note = "Funding Information: Conflict-of-interest disclosure: J.D.G., J.S., and G.A.B. are inventors on a patent (Patent Cooperation Treaty patent application PCT/US18/15918) submitted by The Children{\textquoteright}s Hospital of Philadelphia that covers the therapeutic targeting of HRI for hemoglobinopathies. G.A.B holds licensing agreements with Pfizer Inc and Vertex Pharmaceuticals and has received research funding from Pfizer Inc and served as a consultant for Fulcrum Therapeutics. The remaining authors declare no competing financial interests. Funding Information: This work was supported by National Institutes of Health, National Heart, Lung, and Blood Institute grants R01HL119479 (G.A.B.) and T32HL007439 (S.A.P); Doris Duke Charitable Foundation Physician Scientist Fellowship grant 2020062 (S.A.P.); the St Jude Children{\textquoteright}s Research Hospital Collaborative Research Consortium on Novel Gene Therapies for Sickle Cell Disease; research funding from Pfizer Inc (G.A.B); and a generous gift from the DiGaetano family.",
year = "2000",
doi = "10.1076/1388-0209(200009)3841-AFT313",
language = "English",
volume = "38",
pages = "313--317",
journal = "Pharmaceutical Biology",
issn = "1388-0209",
number = "4",
}